Narrow-spectrum β-lactamases being inhibited by clavulanic acid (e.g., TEM-1 and TEM-2; SHV-1) or being resistant to the action of clavulanic acid (e.g., IRT, OXAs) have been reported in Proteus spp.

Emblaveo is the first monobactam/beta-lactamase inhibitor and antibiotic combination approved for this condition. The approval was based on results from the phase 3 REVISIT trial. The FDA has ...

Among children treated with oral penicillin or amoxicillin ... This rate is higher than observed in children treated with a beta-lactamase resistant agent, although the associated risk estimate ...

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience. [1 ] Department of Ophthalmology, ...

Drug utilization study using antibacterial agents consumption data. The groups of antibacterial agents most consumed in the hospital complex were carbapenems, penicillins + beta-lactamase inhibitors, ...

This marks the first approval of a fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic for this indication. AbbVie, a prominent player in the biotechnology industry ...

Objective Antimicrobial stewardship (AMS) significantly reduces inappropriate antibiotic use and improves patient outcomes ... We assessed parameter uncertainty using deterministic and probabilistic ...

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author.

The official React Native and Expo components for Stream Chat, a service for building chat applications.

Apollo Hospital's stock ended at Rs 6,761.25 yesterday, showing a 6.57% drop from the previous day, with a trading volume of 213,808 shares.